{Reference Type}: Journal Article
{Title}: Management of Newly Diagnosed Multiple Myeloma Today, and in the Future.
{Author}: Devasia AJ;Lancman GS;Stewart AK;
{Journal}: Hematol Oncol Clin North Am
{Volume}: 38
{Issue}: 2
{Year}: 2024 Apr 2
{Factor}: 2.861
{DOI}: 10.1016/j.hoc.2023.12.007
{Abstract}: Treatment options have expanded rapidly and widely in the past two decades for patients with multiple myeloma. Triplet novel agent-based induction regimens have been accepted as the standard practice wordwide over the last decade both for transplant-eligible and non-eligible patients. The addition of anti-CD38 monoclonal antibodies as part of quadruplet regimens has led to even deeper and longer-lasting responses. The impressive results shown by the quadruplets havebeen practice-changing where accessible in recent years. Chimeric antigen receptor T cell therapy and bispecific antibodies are being tested in the upfront setting and have the potential to once again shift the paradigm of treatment of newly diagnosed MM.